Vistagen therapeutics announces closing of $100 million underwritten public offering

South san francisco, calif., dec. 22, 2020 (globe newswire) --  vistagen therapeutics, inc. (nasdaq: vtgn) (“vistagen”), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (cns) disorders, today announced the closing of its $100 million underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “common stock”), and 2,000,000 shares of its series d convertible preferred stock (“series d preferred stock”) at a public offering price of $21.16 per share. all of the securities in the offering were sold by vistagen.
VTGN Ratings Summary
VTGN Quant Ranking